Navigation Links
Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/5/2007

- Company Will Present Seven Posters and sponsor Satellite Symposium at Key

Scientific Gathering at McCormick Place in Chicago, September 17

- 20 -

CHICAGO, Sept. 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), will present seven posters on selected cethromycin therapeutic studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at McCormick Place in Chicago, September 17 - 20. ICAAC, a key scientific event expected to attract more than 12,000 scientists from around the world, is a gathering of leading researchers and clinicians to discuss important themes and present the newest treatment advances in infectious disease. The Advanced Life Sciences booth, #643, will be located in Hall D in the Lakeside Center at McCormick Place.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO)

The Advanced Life Sciences poster presentations will discuss in vitro activity of cethromycin against key susceptible and resistant pathogens involved in community acquired pneumonia (CAP) as well as safety data in certain special clinical populations. Along with collaborators such as the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Eurofins Medinet, Micromyx and Battelle, the Company will present data demonstrating the potency of cethromycin against pathogens involved in bioterrorism.

In addition, Advanced Life Sciences is sponsoring a satellite symposium entitled "Drug Resistant CAP, Current and Future Treatments: Best Practices for Prevention and Management". The panel, moderated by Gerald Donowitz, M.D., will feature presentations by Richard Wunderink, M.D., Joseph Blondeau, Ph.D. and B. Joseph Guglielmo, Jr., Pharm.D., all thought leaders in the field of infectious disease and microbiology. The satellite symposium is supported by Advanced Life Sciences through an unrestricted educational grant to the American Society for Microbiology and Conexus Health.

Symposium and Presentation Schedule

Monday, September 17, 7:00 p.m. Central Daylight Time, Room E354A

-- Satellite Symposium: Drug Resistant CAP, Current and Future Treatments:

Best Practices for Prevention and Management

Tuesday, September 18, 11:15 a.m. Central Daylight Time, Room E253D

Poster Session 222: Pathogenesis and Therapeutics in Agents of

Bioterrorism

-- Poster: Poster B-2031: Efficacy of Cethromycin Against a Lethal

Inhalation Anthrax Challenge in Rhesus Macaques

Wednesday, September 19, 12:15 p.m. Central Daylight Time, Hall D

Poster Session 176: Macrolides, Ketolides, Bicyclolides and Quinolones

-- Poster E-1633: Assessment of In Vitro Activity of Cethromycin Against

Telithromycin-resistant Strains of Streptococcus pneumoniae

-- Poster E-1632: Assessment of In Vitro Activity of Cethromycin Against

Strains of Streptococcus pneumoniae

-- Poster E-1631: Assessment of In Vitro Activity of Cethromycin Against

Strains of Haemophilus influenzae

-- Poster E1634: Antimicrobial Activity of Cethromycin, a Novel Ketolide,

Tested against a Diverse Collection of Francisella tularensis Strains

Thursday, September 20, 9:00 a.m. Central Daylight Time, Hall D

Poster Session 82: New Drug Pharmacokinetics

-- Poster A-797: Evaluation of the Safety and Pharmacokinetics of

Cethromycin Following Administration of Multiple Doses to Subjects with

Severe Renal Impairment

-- Poster A-796: Evaluation of the Safety and Pharmacokinetics of

Cethromycin Following Administration of Single and Multiple Doses to

Subjects with Mild or Moderate Chronic Hepatic Insufficiency

About ICAAC

The American Society for Microbiology (ASM) is hosting the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which will be held in Chicago, Illinois, September 17 - 20, 2007. More than 12,000 physicians, researchers and other healthcare professionals from around the globe gather each year at ICAAC to foster worldwide solutions to the challenges of infectious diseases.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections.

Forward-Looking Statements

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
10. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016   Arena Pharmaceuticals, Inc. (NASDAQ: ... enrollment in the ralinepag phase 2 trial.  Ralinepag is ... pathway for the treatment of pulmonary arterial hypertension (PAH). ... "This marks an important step in the ... focus on our pipeline," said Amit Munshi , ...
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... Dec. 7,2016  Based on its recent ... Frost & Sullivan recognizes Nemaura Pharma Limited ... Award for Enabling Technology Leadership. Nemaura Pharma,s ... in traditional drug delivery technologies, especially in ... drug delivery technologies, Memspatch and Micropatch respectively, ...
Breaking Medicine Technology:
(Date:12/7/2016)... NY (PRWEB) , ... December 07, 2016 , ... A. ... business owners and families throughout the Five Boroughs, is launching a charity drive to ... works to continue the traditions and spirit of marines and Navy FMF Corpsmen. Working ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu ... fully redesigned website, which launched October 17, 2016, features comprehensive information regarding a ... easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology treatments for ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... condemning "scam operations" carried out by unethical locksmith companies and is urging Search ... a halt. According to Texas Premier Locksmith, these fraudulent locksmith services take advantage ...
(Date:12/7/2016)... ... 07, 2016 , ... "ProBrand Flip allows FCPX editors to create unique logo ... CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip book reveal animations. ... select from a variety of flip book animations. In Addition, users can modify each ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
Breaking Medicine News(10 mins):